Himanshu Rastogi, Gaurav Sharma, Asha Sharma, Snehasis Jana
Himanshu Rastogi1, Gaurav Sharma1*, Asha Sharma2, Snehasis Jana3
1School of Applied Sciences, Suresh Gyan Vihar University, Jaipur -302025, India.
2Department of Zoology, Swargiya PNKS Government PG College, Dausa-303303, India.
3Drug Discovery Research and Development Division, Trivedi Science Research Laboratory Pvt Ltd,
Volume - 13,
Issue - 12,
Year - 2020
Background and objective: Dietary flavones like chrysin are found in foods and can contribute to human health through prevention of cardiovascular and cancer supplements. Recently, as herbal medicines and traditional allopathic medicines are used together, drug food or herbal drug interactions have become the target of our body and can lead to potential herbal-drug interactions. The present study aims to determine the metabolic stability and CYP inhibition liabilities in human liver microsomes in order to rule out the association between herb drugs and the dietary flavone chrysin. Methods: Standard procedures were used for metabolic stability study in human liver microsomes (Phase I) and metabolic stability study in cryopreserved human hepatocytes (Phase II). Human liver microsomes (HLMs) were added to each selective probe substrates of cytochrome P450 enzymes with or without of chrysin and IC50 was calculated. Results: Metabolic stability data reveals that Chrysin underwent phase II metabolism predominantly as it was highly stable in HLM and comparatively faster metabolism in hepatocytes. Chrysin was found to be a potent inhibitor of CYP1A2 and CYP2C9 with IC50 values of 0.6 µM and 1.6µM, respectively. Chrysin has weak inhibitory effect on other CYP isoforms such as CYP2C9, CY2D6 (~25µM) and no inhibition of CYP3A4 up to 100µM. Conclusion: These results could be useful in clinical practice for safely and effectively use of flavone chrysin. Our report showed that in vivo interactions of drugs and pharmaceuticals with dietary flavones must be examined for CYP1A2 and CYP2C9 substrates.
Cite this article:
Himanshu Rastogi, Gaurav Sharma, Asha Sharma, Snehasis Jana. In-Vitro Assessment of the Inhibitory effects of Dietary flavones on the regulated metabolism of CYP 450: Potential for Herb-drug interactions. Research J. Pharm. and Tech. 2020; 13(12):6086-6092. doi: 10.5958/0974-360X.2020.01061.6
1. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2(12):1231–46.
2. Kumar S, Pandey AK. Chemistry and Biological Activities of Flavonoids: An Overview. Lu KP, Sastre J, editors. Sci World J 2013;2013: 162750.
3. Kočevar N, Glavač I, Kreft S. Flavonoidi. Farm Vestn. 2007;58(4):145–8.
4. Jiang W, Hu M. Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways. RSC Adv. 2012;2(21):7948–63.
5. Zhu R, Hu L, Li H, Su J, Cao Z, Zhang W. Novel natural inhibitors of CYP1A2 identified by in silico and in vitro screening. Int J Mol Sci. 2011;12(5):3250–62.
6. Noh K, Oh DG, Nepal MR, Jeong KS, Choi Y, Kang MJ, et al. Pharmacokinetic interaction of chrysin with caffeine in rats. Biomol Ther. 2016;24(4):446–52.
7. Scalbert A, Williamson G. Chocolate: Modern Science Investigates an Ancient Medicine. J Med Food. 2000;3(2):121–5.
8. Cheung Y, Meenu M, Yu X, Xu B. Phenolic acids and flavonoids profiles of commercial honey from different floral sources and geographic sources. Int J Food Prop [Internet]. 2019;22(1):290–308.
9. Silva De Paula E, Carneiro MFH, Grotto D, Hernandes LC, Antunes LMG, Barbosa F. Protective effects of niacin against methylmercury-induced genotoxicity and alterations in antioxidant status in rats. J Toxicol Environ Heal - Part A Curr Issues. 2016;79(4):174–83.
10. Maruhashi R, Eguchi H, Akizuki R, Hamada S, Furuta T, Matsunaga T, et al. Chrysin enhances anticancer drug-induced toxicity mediated by the reduction of claudin-1 and 11 expression in a spheroid culture model of lung squamous cell carcinoma cells. Sci Rep [Internet]. 2019;9(1):1–14.
11. Balam FH, Ahmadi ZS, Ghorbani A. Inhibitory effect of chrysin on estrogen biosynthesis by suppression of enzyme aromatase (CYP19): A systematic review. Heliyon [Internet]. 2020;6(3): e03557.
12. Izzo AA. Herb-drug interactions: An overview of the clinical evidence. Fundam Clin Pharmacol. 2005;19(1):1–16.
13. Bai J, Zhao S, Fan X, Chen Y, Zou X, Hu M, et al. Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo: Food/herb-drug interactions and structure–activity relationships. Toxicol Appl Pharmacol. 2019;369(December 2018):49–59.
14. Rastogi H, Jana S. Evaluation of inhibitory effects of caffeic acid and quercetin on human liver cytochrome P450 activities. Phyther Res. 2014; 28(12):1873–8.
15. Food and Drug Administration. Clinical Drug Interaction Studies — Study Design, Data Analysis, and Clinical Implications Guidance for Industry Clinical Drug Interaction Studies — Study Design, Data Analysis, and Clinical Implications Guidance for Industry. Us Fda. 2017;(October).
16. Pingili RB, Pawar AK, Challa SR. Systemic exposure of Paracetamol (acetaminophen) was enhanced by quercetin and chrysin co-administration in Wistar rats and in vitro model: Risk of liver toxicity. Drug Dev Ind Pharm. 2015;41(11):1793–800.
17. Telluri S, Pandu P, Kilaru NB, Pingili RB. Influence of Chrysin on the P-Glycoprotein and CYP3A4-Mediated Intestinal Permeability of Felodipine, Diltiazem and Metoprolol Using Rat Gut Sac Model. 2019;21–8.
18. Walle T, Otake Y, Brubaker JA, Walle UK, Halushka P V. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol. 2001;51(2):143–6.
19. Dinger J, Meyer MR, Maurer HH. Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail. Anal Bioanal Chem. 2014;406(18):4453–64.
20. Malki MA, Pearson ER. Drug–drug–gene interactions and adverse drug reactions. Pharmacogenomics J. 2019;
21. Polasek TM, Lin FPY, Miners JO, Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: A criteria-based assessment. Br J Clin Pharmacol. 2011;71(5):727–36.
22. Pragyan P, Kesharwani SS, Nandekar PP, Rathod V, Sangamwar AT. Predicting drug metabolism by CYP1A1, CYP1A2, and CYP1B1: insights from Meta Site, molecular docking and quantum chemical calculations. 2014;
23. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: Food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727–47.